Sequenom Inc. (SQNM) Laboratories Grants Nicox Exclusive Promotion And Marketing Rights For Its Retnagene™ AMD Test In North America
1/16/2014 9:10:45 AM
SOPHIA ANTIPOLIS, France and SAN DIEGO, Jan. 16, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene(TM) AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjö(TM), an advanced diagnostic panel for the early detection of Sjögren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by